ArticlebioRxiv : the preprint server for biology2026
mChIP-seq for Multiplex and Multifactorial Epigenomic Profiling Uncovers Cancer-specific Histone Features in Cellular and Circulating Nucleosomes.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenomic profiling facilitates access to investigate regulatory roles of histone marks in a type-specific cell, and serves as a critical path for discovering noninvasive epigenetic models in cell-free nucleosomes. Here, we present mChIP-seq, an epigenomic profiling technology that is compatible with both cell and cell-free samples for synchronously profiling multifactorial epigenetic landscapes on multiple samples. Combining sample indexing in a single reaction with a pool-and-split strategy for immunoprecipitation, mChIP-seq enhances efficiency and reduces cost. Using mChIP-seq, we profiled H2A.Z and 10 histone modifications in cell lines representing 9 cancer types. Integrative analyses further revealed an atypical association of H2A.Z and H3K4me3 at promoter regions in cancer. Based on mChIP-seq, we developed cf-mChIP-seq for circulating nucleosomes, which requires as little as 25 μl of plasma per profile. Profiling 38 plasma samples for H2A.Z, H3K4me3, H3K27ac, and H3K9me3 with cf-mChIP-seq revealed distinct histone mark-associated cfDNA fragment patterns in breast cancer versus healthy control, highlighting the potential of cf-mChIP-seq to expand liquid biopsy methodologies. These results demonstrate that mChIP-seq is a widely applicable technology for large-scale epigenomic profiling of nucleosomes in cellular or cell-free forms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.